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Copper is an essential element, and either a copper deﬁciency or excess can be life threatening. Recent
studies have indicated that alteration of copper metabolism is one of the pathogenetic mechanisms of
Alzheimer’s disease (AD). In light of these ﬁndings, many researchers have proposed preventive stra-
tegies to reduce AD risk. Because the general population comes in contact with copper mainly through
dietary intake, that is, food 75% and drinking water 25%, a low-copper diet can reduce the risk of AD in
individuals with an altered copper metabolism. We suggest that a diet-gene interplay is at the basis of
the “copper phenotype” of sporadic AD. Herein, we describe the pathways regulating copper homeo-
stasis, the adverse sequelae related to its derangements, the pathogenic mechanism of the AD copper
phenotype, indications for a low-copper diet, and future perspectives to improve this preventive strategy.
 2014 Elsevier Inc. Open access under CC BY-NC-ND license.1. Introduction
Alzheimer’s disease (AD) is the most common form of dementia,
and the increase in the aging rate of developing countries portends
a signiﬁcant increase in its prevalence in coming years. A large
portion of the world’s public health expenditures is AD related,
directly or indirectly (Alzheimer’s Disease International, 2010).
Furthermore, AD affects the quality of life of people afﬂicted with
the disease and their family members, who are, in most of cases,
their primary caregivers (Wimo et al., 2013). Accordingly, effective
strategies to prevent or to postpone AD onset are clearly needed. To
date, only symptomatic treatments are available for AD, and these
medications offer modest beneﬁts without a curative impact
(Herrmann et al., 2011).
Regarding preventive strategies, several factors have been
identiﬁed to estimate AD risk (i.e., age, sex, family history, the
presence of the APOE4 allele, systolic blood pressure, body mass
index, total cholesterol level, and physical activity) and severaltion for Health Research and
9 06 6837 385; fax: þ39 06
Y-NC-ND license.hypotheses to prevent AD have been postulated (Gauthier et al.,
2012). Although there are many technical challenges in designing
AD preventive trials, this remains a crucial area of research (Andrieu
et al., 2009; Gauthier et al., 2012).
Among the modiﬁable lifestyle-related factors associated with
AD risk, diet has demonstrated some interesting results. Specif-
ically, certain diets (e.g., Mediterranean-type diets) have been
associated with a lower incidence of AD (Gardener et al., 2012; Soﬁ
et al., 2010). Two nutrition-related links could connect diet and the
development of AD, that is, micronutrients and macronutrients
(Bourre, 2006a, 2006b). Deﬁciencies of some micronutrients,
especially those related to antioxidant and amino acid metabolism
mechanisms (e.g., vitamins B1, B2, B6, B12, C, and folate), have been
associated with cognitive impairment in elderly people (Solfrizzi
et al., 2011). A high intake of speciﬁc dietary factors (e.g., satu-
rated fatty acids) enhances the amyloid-beta (Ab) deposition in the
animal model brain and increases oxidative stress (Solfrizzi et al.,
2011). The relationship between speciﬁc fats and AD risk may
relate, at least in part, to the actions of APOE, which is involved in
the transport and metabolism of lipids. In addition to nutrients, a
number of neurotoxic substances are consumed through the diet. In
some cases, these compounds have been associated with an in-
crease in AD risk.
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pounds and as essential elements for a wide range of physiologic
functions. In some cases, their ingestion is associatedwith the onset
of neurotoxic effects. For instance, some studies have investigated
the role that aluminum exposure plays in AD risk. Epidemiologic
evidence suggests that aluminum in the diet may modify AD risk
(Frisardi et al., 2010; Tomljenovic, 2011). It has also been postulated
recently that environmental exposure to lead may result in epige-
netic changes associated with AD pathogenesis (Bakulski et al.,
2012). In some cases, the transition from a physiological condition
to a pathologic one is precipitated by an altered state of metal-
related metabolism, especially in regard to transition metals, such
as iron, copper, and zinc.
Regarding metal dyshomeostasis in AD, several research groups
have hypothesized that alterations in metal metabolism are asso-
ciated with an increase in metal-related oxidative stress, which
contributes to Ab toxicity and Ab oligomer formation and precipi-
tation. Following this line of thought, one of the most recent con-
cepts in AD pathogenesis is that alterations of copper metabolism
associated with genetic defects are associated with a “copper
phenotype” in a large percentage of AD patients. This hypothesis,
supported by recent evidence (Bonda et al., 2011; Squitti and
Polimanti, 2013), is changing the way scientists view AD. It also
suggests unexpected routes for AD prevention. In fact, although
scientists have yet to fully grasp how foods inﬂuence a person’s risk
of developing AD, a recent study has elucidated the detrimental
effect of altered coppermetabolism (copper dyshomeostasis) on AD
(Squitti and Polimanti, 2013).
The amount of literature available on dysfunction of copper
metabolism has reached such a critical mass that dietary changes
may be justiﬁed. In fact, these changes may be justiﬁed not only in
cases in which available evidence demonstrates risk beyond any
doubt but also in cases in which evidence of risk is substantial.
Accordingly, individuals with an established diagnosis of copper
dysfunction who choose to implement a low-copper diet may
reduce their risk of AD. In this review, we describe the mechanisms
of dietary copper intake and absorption, the relationship between
defects in copper metabolism and human diseases, and the basic
tenets of a low-copper diet.
2. Copper homeostasis
Copper homeostasis is determined by the equilibrium between
the rates of dietary absorption from food and drinking water and
excretion through stools and bile (Fig. 1). The World Health Orga-
nization (WHO) has classiﬁed copper as an essential element with
the following statement: “absence or deﬁciency of the element
from the diet produces either functional or structural abnormalities
and that the abnormalities are related to, or consequence of, spe-
ciﬁc biochemical changes that can be reversed by the presence of
the essential metal” (WHO, 1996). Excess copper can also lead to
undesirable and life-threatening effects (de Romana et al., 2011).
Consequently, the equilibrium between the rates of copper ab-
sorption and copper excretion is tightly regulated.
2.1. Copper intake and absorption
According to theWHO, theminimal acceptable intakeof copper is
about 0.9e1.3 mg per day, whereas, the average person consumes
w2 mg per day (WHO,1996). Ingesting 2e3mg per day of copper is
safe and adequately prevents copper deﬁciency. However, ingesting
>5 mg per day is considered toxic. In a normal individual, ingestion
of a higher quantity of copper has little or no effect on its absorption
because under normal conditions, the amount of copper absorbed in
the upper gastrointestinal tract is generally w0.5 mg per day(Hoogenraad, 2001) and the remaining amount of copper with
respect to the quantity coming from dietary intake is directly elim-
inated without entering pathways of absorption. This occurs mainly
through the use of metallothioneins, which function as a “mucosal
block” for copper bioavailability. Copper absorption corresponds to
w30% of an individual’s copper intake; however, an elegant exper-
iment in the late 1980s clearly demonstrated that copper absorption
dependsondietarycopper intake (Turnlundet al.,1989). Speciﬁcally,
copper absorption decreases as dietary copper intake increases, and
it canvary from0.43mgperday (corresponding to56%of the dietary
copper intake during a low-copper regimen: 0.79 mg per day for 42
days) to 0.9 mg per day (corresponding to 12% under a high-copper
regimen diet: 7.53mgper day). At a high-copper intake regimen, the
efﬁciency of copper absorption declines, but more copper is absor-
bed and retained (Turnlund et al., 2005).
In themucosal cells of the intestine,metallothioneins tightly bind
copper and block its absorption. Copper is trapped in metal-
lothioneins, and it is not transferred into the general circulation. The
exfoliation of mucosal cells, when enterocytes are shed into the in-
testinal lumen and released with feces, allows for copper removal.
This process occurs without depleting the bioavailable reservoir of
copper. Theexpressionofmetallothioneins canbemodulatedbyzinc,
which can increaseby25-fold theexpressionof thesenatural copper-
trapping proteins. In the upper gastrointestinal tract, copper is
absorbed as lowemolecular-weight-soluble complexes of copper
(Kim et al., 2003). This copper fraction is mainly bound to amino
acids, small peptides, micronutrients, and albumin. In this form, it is
transported into the serum and released to be absorbed into the
tissues. Fromthegut, this lowemolecular-weight copper, alsoknown
as “free,” labile, or non-ceruloplasmin (non-Cp), reaches the liver
through the portal circulation. The liver absorbs most of this copper
and limits its concentration in the blood to 0.008e1.6 mmol/L that
corresponds to 0.05e1 mg/dL. This is the normal reference range of
non-Cp copper in serum after an overnight fast (Hoogenraad, 2001).
The liver functions as a chemical laboratory for copper and pro-
cesses this highly reactive metal with specialized proteins, which
allows copper (Cuþ) to enter the hepatocyte and pass through hu-
man copper transporter 1. These proteins then accompany the
copper to the sites of utilization. In the hepatocyte, copper is incor-
porated into copper proteins and enzymes that regulate a number of
vital biologic processes including cytochromes in the mitochondria
for oxidative respiration, Cu/Zn superoxide dismutase for antioxi-
dant defenses, Cp for regulating the iron oxidative state, and distri-
bution to tissues and organs (for detailed molecular pathways, refer
to Gaggelli et al., 2006; Squitti et al., 2013d). The main pathway
involved in copper balance in the hepatocyte also involves Cp and
the key protein pump ATP7B. Copper enters the hepatocyte through
human copper transporter 1 (CTR1), and it is subsequently bound by
ATOX1, which transfers themetal to ATP7B that, in turn, mounts the
copper into the nascent Cp in the trans-Golgi network.When copper
exceeds the needs of the cell, ATP7B moves toward the cell mem-
brane, and, via hepatic lysosomes, copper is released in the bile
canaliculus togetherwith thedegradationproducts of Cp. ATP7B and
Cp cooperate in regulating copper excretion and release copper
complexes into the bile (Verbina et al., 1992).
2.2. Copper excretion
The lowemolecular-weight copper leaves the gut and moves to
the liver via the portal circulation. Given an absorption rate of
0.5 mg per day (that can range between 12% and 56%), approxi-
mately 0.2e0.5 mg of copper is released through the bile. The
remaining copper is used for the Cp (200 mg/mL) and other copper
protein biosynthesis. The majority of copper taken in through
the diet, however, is not absorbed. Rather, it accumulates into
Fig. 1. The normal pathway for copper absorption. Copper dietary intake in 24 hours is 1.5 mg; 0.5 mg per day of this copper is absorbed from duodenum and transported to the liver
through the portal system. In the liver, the copper is structurally incorporated into ceruloplasmin (Cp) by the copper pump ATP7B. Normal values of Cp are >20 mg/dL; the
concentrations of non-Cp copper and urinary copper after an overnight fast are <1.6 mmol/L. Red box indicates the hepatocyte. A still unknown reductase protein reduces Cu2þ to
Cuþ, which is then imported into the cell by human copper transporter 1 (hCTR1). Once in the cell, copper is carried by cytochrome C oxidase assembly homolog (COX17) to the
mitochondria, by the copper chaperone for superoxide dismutase (CCS) to the superoxide dismutase (SOD) and by the antioxidant protein 1 homolog (ATOX1) to the ATP7B. In the
trans-Golgi network (TGN), the ATP7B protein loads copper into nascent apo-Cp to form active holo-Cp.
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through urine is negligible and accounts for <0.05 mg per day.
Turnlund et al. (1990) reported a value of copper in the sweat in the
same order of magnitude as urinal copper losses. However, an
earlier study found copper losses in sweat to be 10-fold greater and
reported a value ofw0.34 mg per day (Jacob et al., 1981).
3. Copper metabolism and human diseases
Defects in the pathways controlling copper homeostasis result
in serious health consequences, speciﬁcally for brain health and
development. This is well exempliﬁed by 2 genetic disorders that
are alternately characterized by deﬁciency (Menkes disease [MD])and excess (Wilson disease [WD]) of total body copper content. In
these diseases, the genes coding for the 2-membrane copper
transport proteins known as copper pumps ATP7A and ATP7B are
mutated (Kodama et al., 2012).
3.1. Menkes disease
MD is the paradigmatic disease for copper deﬁciency. MD is
caused by mutations in the ATP7A gene that encode for P-type
copper-transporting ATPase 1 (ATP7A) (Bertini and Rosato, 2008).
This protein is widely expressed in human tissues and allows
copper to enter into the bloodstream by passing through enter-
ocytes. Mutations of ATP7A prevent copper absorption at the
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copper being poorly distributed to cells in the body. Copper accu-
mulates in some tissues, that is, the small intestine and kidneys,
whereas the brain and other tissues have unusually low levels
(Kaler et al., 1994). This abnormal copper distribution induces
different clinical manifestations including growth failure and the
deterioration of the nervous system (Kaler, 2011).
Signs of MD include weak muscle tone, sagging facial features,
seizures, mental retardation, blue sclera, and developmental delay
(Kaler, 1994). The disease onset typically begins during infancy. In
some cases, copper deﬁciency inMD is so severe thatmale fetuses die
during gestation because MD is an X-linked recessive disorder
(Tumer, 2013). The neurologic symptoms of MD are likely caused by
the localization of ATP7A in the brain. ATP7A is expressed in the
polarized brain capillary endothelial cells of the blood-brain barrier.
This copper pump is localized in the basolateral surfaces, which
deliver copper from the blood to the brain (Choi and Zheng, 2009).
Moreover,ATP7A ishighlyexpressed inchoroidplexusepithelial cells,
and ATP7A protein is thought to be localized at the apical membrane
of these cells,which suggests thatATP7Aplays a role in thedeliveryof
copper to cerebrospinal ﬂuid (CSF) (Choi and Zheng, 2009).
Early diagnosis and treatment with copper intravenous infusion
increase the likelihood of the survival of MD patients. However,
therapy can normalize signs and symptoms of the disease only in
patients with ATP7Amutations that have mild effects on the protein
activity (Kaler, 2011).
3.2. Wilson disease
WD is caused by a defect in copper excretion and is the para-
digmatic disease of copper accumulation or intoxication. Defects
of ATP7B cause copper overload and intoxication in the liver and
then in the brain and other organs. The irises of afﬂicted patients
are often encircled by Kayser-Fleischer rings because of copper
accumulation in the cornea (Descemet membrane) (Fig. 2).
Kayser-Fleischer rings are 1 of the 6 markers used to suggest the
WD diagnosis (Bakulski et al., 2012). These markers are diagnos-
tically important because the clinical presentation is variable and
is inﬂuenced by additional hereditary factors. A case in point was
reported in 1981, when researchers identiﬁed late-onset cases of
WD among 5 family members, each of whom displayed different
clinical symptoms, from a psychiatric manifestation, to hepatic
disease, to neurologic symptoms, and even asymptomatic siblings
(Czlonkowska and Rodo, 1981). This example demonstrates the
complexity of the diagnosis, the relevance of a biologic marker
intended to identify the biologic lesion (non-Cp copper higher
than the normal) rather than the clinical presentation, along with
the relevance of the interplay between genetics and the diet and,
generally, the lifestyle because the siblings were affected by the
same ATP7Bmutation. Evidence also suggests that the onset of WD
usually occurs earlier in patients with hepatic symptoms than in
those with neurologic manifestations, suggesting a dosage effect
of copper intoxication that is inversely associated with the
severity of the biologic lesion. When the lesion is more severe, it
affects the liver acutely, and when it is less severe, it takes years or
even decades to affect brain functionality. A defect in the ATP7B
gene causes abnormal copper pumping through the trans-Golgi
vesicles and impairment of copper incorporation into nascent Cp
and copper excretion through the bile. Schematically, in WD,
copper absorption is normal, but copper incorporation into Cp and
bile excretion is defective. Accordingly, copper accumulates in the
hepatocytes, and there is an excess of copper in the blood, thus
increasing the concentration of non-Cp copper. Non-Cp copper
values in normal individuals are <1.6 mmol/L after an overnight
fast, but in WD-affected individuals, they are notably higher.Except for speciﬁc cancers, acute inﬂammatory states, acute liver
failure, and chronic cholestasis, no other altered biologic pathway
can cause increased levels of non-Cp copper after an overnight
fast. This enables researchers to identify a clear metabolic defect in
the bottleneck step of the copper excretion pathway involving
ATOX1 and ATP7B.
3.3. Alzheimer’s disease
The late-onset type of AD is a disease with a complex etiology.
Several hypotheses have been made to explain its onset (Ballard
et al., 2011). The “amyloid cascade” is the most popular hypothe-
sis to date, and several lines of research are contributing new
details about the disease pathogenesis (Reitz, 2012). Oxidative
stress is one of the most relevant processes as it damages the AD
brain via Fenton and Haber-Weiss chemistry (Jomova et al., 2010).
Different studies indicate that copper can play a key role in these
pathogenic processes. A number of molecular studies have also
demonstrated that the hypermetallation of Ab peptides can cause
oxidative stress, H2O2 production, and Ab plaques (reviewed in
Squitti, 2012b), and clinical, epidemiologic, and meta-analysis
studies support these ﬁndings (reviewed in Squitti and
Polimanti, 2013).
Although AD shares withWD increased values of non-Cp copper
after an overnight fast, thus resembling the same biologic lesion
typifying WD, the values are less severe than those of WD. Never-
theless, the correlations with clinical symptoms and markers in the
CSF of AD demonstrate a link between copper intoxication and AD
(reviewed in Squitti, 2012a). The increase of non-Cp copper level in
the general circulation causes an increase of the non-Cp copper
level in the brain (Fig. 3), as exempliﬁed by WD, and was recently
found in postmortem brain samples from AD patients (James et al.,
2012). Non-Cp copper in the brain can likely overwhelm homeo-
static processes and trigger the activation of the previously
described copper-related amyloid cascade. Although AD cannot be
considered the “senile” form of WD, current experimental evidence
on copper dyshomeostasis in AD indicates that these disorders
share a pathogenetic mechanism. This strongly suggests that cur-
rent knowledge about WD therapy can be translated into AD pre-
vention or care.
3.4. Other diseases
Systemic changes caused by alterations of copper metabolism
have been associated with other chronic diseases, for example,
diabetes, cardiovascular diseases, and atherosclerosis. Also, an in-
crease in copper levels is established in speciﬁc cancers (i.e., breast,
cervical, ovarian, lung, prostate, stomach, and leukemia). Apart
from inﬂammatory processes, the association between copper
dyshomeostasis and carcinogenesis is likely because of the
enhancement of copper-related oxidative stress that is correlated
with the activation of several factors involved in the predisposition
to tumor onset and progression (e.g., increased basal metabolism,
mitochondrial mutations, and cytokines). It has been recently
postulated that copper may also be associated with epigenetic
changes; disarrangements of copper physiological metabolism may
inﬂuence gene expression, leading to nonphysiological conditions
that may evolve into carcinogenesis.
Patients with diabetes show higher plasma copper concentra-
tions, compared with those of healthy individuals. Accordingly,
molecular studies have indicated that copper alterations can
interact with glycated proteins in the formation of free radicals and
increase oxidative stress. This seems to be in agreement with the
relationship between copper overload and presence of diabetes
complications (e.g., hypertension and retinopathy).
Fig. 2. Copper absorption in patients with Wilson disease. Absorption is normal, but there is a failure in its incorporation into ceruloplasmin (Cp). Red box indicates the hepatocyte.
ATP7B functionality is impaired (black cross). This causes a decrease in copper excretion through the bile and an overﬂow of non-Cp copper in general circulation and urine. The
overload of non-Cp copper in systemic circulation causes brain copper deposits and, in a certain percentage of patients, Kayser-Fleischer rings in the iris of eyes. Values of Cp are <20
mg/dL; the concentrations of non-Cp copper and urinary copper are >1.6 mmol/L.
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The interaction between copper and homocysteine generates free
radicals and, consequently, leads to oxidized low-density lipo-
protein (Nakano et al., 2004). The alteration of copper metabolism
may also affect endothelial activation by stimulating redox-
sensitive cell signaling pathways via redox activity of metal ions
(Wei et al., 2012). Finally, experiments on animal models indicate
that copper chelation through tetrathiomolybdate inhibits vascular
inﬂammation and atherosclerotic lesion development (Wei
et al., 2012).
Some disorders caused by acquired copper deﬁciency include
rare diseases of anemia and neutropenia (Wu et al., 2006). Copper
deﬁciency myelopathy is the most representative copper
deﬁciency-related disease, and risk factors include gastrointestinal
surgery, zinc overload, and malabsorption syndromes that are all
associated with impaired copper absorption in the upper gastro-
intestinal tract (Jaiser and Winston, 2010).4. Relationship between copper increase and AD risk
Since 2002, we have been carrying out a series of studies inves-
tigating the link between copper and AD risk. In these studies, we
have analyzed the interplay between copper and other metal
markers and the clinical picture of AD. Speciﬁcally, we have inves-
tigated copper in relation to cognitive performance as measured by
the mini-mental state examination and the other tests of the neu-
ropsychological dementia battery, in relation to electroencephalo-
graphic examinations, neuroimaging investigations, markers of AD
in the CSF, and genetics. From these studies, data have arisen about
the risk of developing AD on the basis of a copper dyshomeostasis.
Applying models of logistic regression analysis, an increase of 1
mmol/L in total serum copper accounted for 80% of the risk of having
AD, aswedetermined in an initial study (Squitti et al., 2002). The risk
doubles if the comparison ismadebetweenADpatients and subjects
affected by vascular dementia (Squitti et al., 2003).
Fig. 3. Model of copper absorption in Alzheimer’s disease patients. Absorption is normal, but there is a failure in its incorporation into ceruloplasmin (Cp). Red box indicates the
hepatocyte. ATP7B functionality is impaired (black cross), although less severely with respect to Wilson disease. This causes an overﬂow of non-Cp copper sufﬁciently to be detected
in general circulation. Green box indicates the brain. When values of non-Cp copper exceed 1.6 mmol/L, it crosses the brain blood barrier (BBB) and enters Fenton and Haber-Weiss
reactions with amyloid-beta (Ab), producing H2O2, and Ab-plaque deposition. Values of Cp are >20 mg/dL, and the concentration of non-Cp copper is >1.6 mmol/L.
R. Squitti et al. / Neurobiology of Aging 35 (2014) S40eS50 S45In subsequent studies, we focused on non-Cp copper and esti-
mated a higher risk because non-Cp copper increments are more
speciﬁc for AD than those of total serum copper. A 1 standard de-
viation increase in non-Cp copper concentration raises the relative
risk ratio of developing AD by 3.21 times (95% conﬁdential interval
[CI] 1.53e6.71, p< 0.002) (Squitti et al., 2013a). Moreover, the effect
of patients’ non-Cp serum copper on the odds of mini-mental state
examination worsening in a year was w23% (odds ratio [OR] 1.23,
95% CI 1.03e1.47, p < 0.022) (Squitti et al., 2009). The relative risk
ratio of having mild cognitive impairment with respect to healthy
controls, depending on non-Cp copper increases in serum, has been
estimated at w22% (Squitti et al., 2011). When we analyzed the
possible effects of having speciﬁc ATP7B gene variants, we observed
a more than two-fold risk of becoming ill with AD comparing car-
riers with noncarriers (Squitti et al., 2013b). The values of copper
risk reported previously have been estimated based on the entiretyof our AD patient cohorts and a comprehensive percentage of AD
patients who have not displayed a copper manifestation of the
disease. We have estimated that individuals with high serum non-
Cp copper (>1.6 mmol/L) are 60%e65% of the total sporadic AD
population that we have examined for metal studies, which can be
approximated at w400 AD patients and 200 mild cognitive
impairment subjects (information available at http://www.j-alz.
com/letterseditor/index.html#March2013).
5. Low-copper diet
5.1. Copper deﬁciency and excess in humans and in animal models
Copper toxicity is not a public health concern; there are few
toxic threats to human health that are caused by copper (Stern et al.,
2007). However, as mentioned previously, nonphysiological copper
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conditions. The paradigmatic genetic diseases of copper malab-
sorption and excretion, MD and WD, respectively, exemplify the
effects of copper deﬁciency and excess in the human body and
represent the 2 extreme conditions of abnormal copper homeo-
stasis. But what is in the middle? Minor genetic defects in the genes
that regulate copper homeostasis can also affect human health. For
example, 2 well-established diseases, Indian childhood cirrhosis
and idiopathic copper toxicosis, illustrate the interplay between
genetic predisposition and environmental copper exposure in
determining the onset of copper toxicosis (Muller et al., 1998; Patra
et al., 2013). These are the unique examples of non-Wilsonian
copper overload hepatic disorders that are caused by increased
dietary copper intake and unidentiﬁed genetic defects (Scheinberg
and Sternlieb, 1996).
For humans, the main sources of environmental copper are food
and drinking water. In normal environmental conditions, metal
absorption via inhalation and skin contact is negligible (de Romana
et al., 2011). However, in individuals with copper metabolism de-
fects, high dietary copper intake can be harmful.
Aged mice fed a copper-deﬁcient diet showed a signiﬁcant
alteration of the concentration of different metal ions (i.e.,
aluminum, copper, iron, calcium, and zinc) in their brain and other
tissues, although they displayed no behavioral changes (Bolognin
et al., 2012). In humans, an acquired copper deﬁciency is caused
mainly by bowel resections, chronic diarrhea, and short bowel
syndrome, all of which result in a decrease in intestinal absorption
(Btaiche et al., 2011). In individuals with these malabsorption
syndromes, pancytopenia and neurologic dysfunction are the most
recurrent clinical manifestations (Prodan et al., 2009).
As previously mentioned, copper deﬁciency myelopathy is one
of the most representative diseases related to an acquired copper
deﬁciency (Jaiser and Winston, 2010). Copper supplementation in
individuals with an acquired copper deﬁciency restores normal
copper status and prevents deﬁciency-related adverse sequelae
(Prodan et al., 2009). Conversely, Long-Evans Cinnamon rats, which
are a natural model of WD, have an early and rapid onset of
fulminant hepatitis on a high-copper dietary regimen, but they
survive long term on a low-copper dietary regimen.
Thus, although a copper overload through high-copper food
consumption has little or no direct effect on body copper content
under normal physiological conditions (Siaj et al., 2012) (also see
Section 2.1), genetic make up can signiﬁcantly change this scenario
because copper intake andgenetics are closely connected in termsof
copper toxicosis: a high, or even normal, copper dietary intake in
individuals with a genetic susceptibility to copper exposure causes
metal toxicosis. This iswell exempliﬁed inWDand in the Long-Evans
Cinnamon rats (through experimental diet manipulations, Brewer,
2012). From the previous ﬁndings, we have postulated that there is
a risk of having a speciﬁc form of sporadic AD, which we have called
“copper AD phenotype,” based on a high-moderate dietary copper
intake in people prone to a copper genetic susceptibility (Squitti and
Polimanti, 2013). The copper genetic susceptibility associated with
AD can be thought of as existing between MD and WD. It is not
sufﬁciently severe to cause AD in and of itself, but it can contribute
additional altered AD pathways to the disease cascade. Regardless, a
low-copper regimen may have a positive effect in controlling this
copper risk, and it may even prevent the disease.
5.2. Low-copper diet speciﬁc for individuals with copper
metabolism disarrangements
Regarding essential metals, it is commonly assumed that the
dose-response relationship is a U-shaped curve. Many people as-
sume that for copper, in particular, the U-shaped dose-responsecurve is asymmetric with a steeper relationship for deﬁciency
than for excess (Chambers et al., 2010; Krewski et al., 2010; Stern,
2010). Although this copper dose-response is sustained by experi-
mental evidence, it does not take into account the genetics of
copper metabolism. Indeed, a number of studies have highlighted
the fact that genetics is one of the most important factors in
determining individual susceptibility to an environmental exposure
(Forsberg et al., 2013; Polimanti et al., 2011; Tenesa and Haley,
2013).
As previously described, experimental evidence strongly sup-
ports the interplay between genetics and dietary copper intake in
body copper toxicosis or accumulation in humans. In addition to the
established evidence for WD, studies have been conducted in vivo,
in vitro, in living patients, and in silico. These studies have
demonstrated that AD is also characterized by local and systemic
disarrangements in copper metabolism (Squitti and Polimanti,
2013). Molecular studies indicate that this copper phenotype in
AD is likely caused by genetic defects in the copper proteins
(chaperones and transporters) that control copper homeostasis.
Speciﬁcally, genetic variants in ATP7B are associated with a signif-
icant increase in AD risk (Bucossi et al., 2011, 2012, 2013; Squitti and
Polimanti, 2012; Squitti et al., 2013b). Moreover, it has been
demonstrated that ATP7B is involved in the modulation of copper
dyshomeostasis in AD patients, and carriers of loss-of-function
ATP7B variants have higher levels of serum non-Cp copper than
noncarriers (Squitti et al., 2013c). In accordancewith these ﬁndings,
individuals with altered copper pathways (i.e., prone to AD copper
risk) can be distinguished from thosewith normal copper pathways
(i.e., not prone to the AD copper risk).
The identiﬁcation of individuals with a higher AD copper risk
can be performed by 1 of 2 approaches. The ﬁrst is a biochemical
method based on the analysis of serum non-Cp copper, looking for
values greater than the normal reference value of 1.6 mmol/L. The
second approach is based on the sequence analysis of genes
involved in copper metabolism (e.g., ATP7B, ATOX1, and COMMD1),
identifying the loss-of-function variants that account for the ge-
netic predisposition of copper dyshomeostasis. Unfortunately,
current knowledge about copper dyshomeostasis in AD prevents us,
at present, from developing a reliable strategy that could be used to
identify individuals with a high risk of developing the AD copper
phenotype. We are currently working in tandem with other re-
searchers to bridge this gap.
Several studies have attempted to use diet-based approaches to
prevent AD (Solfrizzi et al., 2011); however, there is a lack of suit-
able tools that could be used to identify individuals who should be
introduced to the diet. Additionally, there is also a lack of markers
that could adequately evaluate the efﬁcacy of this dietary inter-
vention. Regarding a low-copper diet, the indirect estimation of
non-Cp copper, based on the Walshe formula, is routinely used in
clinical practice related to WD (Walshe and Clinical Investigations
Standing Committee of the Association of Clinical, 2003),
although some theoretical problems preclude its application in
certain cases (information available at http://www.j-alz.com/
letterseditor/index.html#March2013). However, a more reliable
test is becoming available and is based on the direct measurement
of serum non-Cp copper to identify high-risk individuals for a
copper dysfunction and to monitor the efﬁcacy of anti-copper
therapies. In this regard, it has to be noted that detecting total
serum copper, Cp, or non-Cp copper with the Walshe formula in
patients taking an anti-copper chelating therapy does not effec-
tively show the bioavailability of copper. In fact, complexes made of
copper tightly bound to the chelating agent circulate in the
bloodstream and are measured in blood tests, although the copper
that they contain is not bioavailable for cell biology processes
(Squitti, 2012a).
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As mentioned previously, humans primarily absorb copper
through dietary intake. National and international organizations
have deﬁned dietary copper reference values to maintain stable
copper homeostasis. They also hope to prevent the threatening
health conditions linked to its alterations. The WHO deﬁned
0.9e1.3 mg as the minimal copper daily intake (WHO, 1996).
However, the maximum and minimum levels of daily copper intake
likely to pose no risk of adverse effects are relative and should be
adjusted slightly according to gender and age. To date, no reference
values for copper have been determined by WHO for sex and age.
The Food and Nutrition Board of the Institute of Medicine of the
National Academies of Sciences provided the references values
(recommended dietary allowance, adequate intake, maximum level
of daily intake) for dietary copper intake in infants, men, women,
and pregnant and lactating women (Table 1). Particular attention
has to be paid to infants and to women who are pregnant or
lactating (National Research Council, 2001). Infants are more sus-
ceptible to copper deﬁciency than adults. Premature infants, in
particular, often require more copper at birth than full-term infants
because fetuses absorb copper during the last months of pregnancy.
In addition, because fetuses absorb copper via the placenta and
infants absorb copper via breast milk, pregnant and nursingwomen
require slightly more copper than other women. Moreover, non-
nursed infants need to take copper supplements for their ﬁrst
year of life because bovinemilk contains lowamounts of copper. For
men and women with an age between 18 and 70 years, the rec-
ommended dietary allowance has been established at 0.9 mg per
day (Table 1).
Copper is a natural element, and it is present in soil and ground
water. Although some geographic locations contain signiﬁcantly
more copper than others, drinking water encompasses 20%e25% of
the dietary copper ingested bymost humans globally. Some authors
have recently hypothesized that the copper present in drinkingTable 1
Dietary reference intake of copper deﬁned by the Food and Nutrition Board of the
Institute of Medicine at the National Academies of Sciences
Age/status group RDA (mg per day) AI (mg per day) UL (mg per day)
Infants (mo)
0e6 d 200 ND
7e12 d 220 ND
Children (y)
1e3 340 d 1000
4e6 440 d 1000
Males (y)
9e13 700 d 5000
14e18 890 d 8000
19e30 900 d 10,000
31e50 900 d 10,000
50e70 900 d 10,000
>70 900 d 10,000
Females (y)
9e13 700 d 5000
14e18 890 d 8000
19e30 900 d 10,000
31e50 900 d 10,000
50e70 900 d 10,000
>70 900 d 10,000
Pregnancy (y)
18 1000 d 8000
19e30 1000 d 10,000
31e50 1000 d 10,000
Lactation (y)
18 1300 d 8000
19e30 1300 d 10,000
31e50 1300 d 10,000
Key: AIs, adequate intakes; ND, not determinable; RDA, recommended dietary
allowance; ULs, upper levels of tolerable intake.water because of leaching from copper plumbing can increase the
risk for AD (Brewer, 2012).
As drinkingwater comprises only 25% of the average individual’s
dietary copper intake, the main source of copper for humans is food
(Stern et al., 2007). The most relevant sources of dietary copper
include seafood (especially shellﬁsh), organ meats, grains, and le-
gumes. Furthermore, nuts and certain fruits (e.g., lemons, raisins,
coconuts, papaya, and apples) are also rich in copper. Other copper
sources include cereals, potatoes, red meat, and mushrooms. Low-
copper foods include tea, rice, and chicken; hence, these foods
must be consumed in greater amounts to avoid copper deﬁciency.
Table 2 reports the top 10 foods with the highest content in copper.
Cooking, food storage, and food processing also affect the quantity
of copper present in any given food. Long-term cooking substan-
tially reduces the copper content in food. For instance, cooking
beans result in a 50% reduction in their natural copper content. Also,
food processing dramatically affects the copper content. For
example, grain conversion to ﬂour results in a reduction of w70%.
Another important factor in copper absorption is the acidic envi-
ronment of the stomach. Individuals with a reduced stomach acid
(e.g., hypochlorhydria) may have an increased risk for copper
deﬁciency.
Recent studies have highlighted a potential connection between
copper and cholesterol in AD (Hunget al., 2013; Sparks and Schreurs,
2003). These ﬁndings strongly suggest that a diet high in copper and
fat can have a strong effect on an individual’s susceptibility to AD
onset. In accordance with this hypothesis, a high dietary intake of
copper and saturated and trans fats has been linked to accelerated
cognitive decline (Morris et al., 2006). Therefore, individuals with a
genetic predisposition to copper dyshomeostasis should avoid foods
not only rich in copper but also high in fat. Accordingly, to enhance
the effectiveness of a low-copper diet, the analysis of serum non-Cp
copper should be coupled with the analysis of fat level in the blood
(e.g., total cholesterol, high-density lipoproteins, low-density lipo-
protein, and triglycerides).
5.4. Anti-copper medical foods
In addition to avoiding or limiting the consumption of high-
copper foods, researchers have proposed 2 other strategies based
on anti-copper medical foods that may reduce the risk of the AD
copper phenotype. The ﬁrst approach involves the ingestion of
compounds competitive with copper for intestinal absorption (e.g.,
zinc). The second approach is based on the use of chelating agents
to bind excess copper. However, these compounds bind copper so
tightly that they compete with copper proteins and enzymes and
cause adverse effects. As such, they should be used only under
medical supervision.
Zinc ingestion reduces the body’s capacity to absorb copper by
potentiating themetallothioneins block in the intestine (see Section
2.1). Zinc can induce a 25-fold increase of the expression ofTable 2
Top 10 foods with the highest content of bioavailable copper
Food Serving
size (g)
Percent daily value
(copper in mg)
Animal liver (veal) 100 753 (15)
Oysters 100 37e500 (1e8)
Sesame seeds 100 204 (4.1)
Cocoa 100 189 (3.8)
Nuts (cashew) 100 111 (2.2)
Seafood (calamari) 100 106 (2.1)
Sunﬂower seeds 100 92 (1.8)
Sun dried tomatoes 100 70 (1.4)
Pumpkin 100 70 (1.4)
Dried herbs (basil) 100 70 (1.4)
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into enterocytes, which are eliminated through exfoliation with
stools, thus preventing copper transfer into the blood. During
therapy with a dosage of 150 mg per day of zinc, body copper
balance becomes negative, reverting copper compartmentalization
and distribution from the blood to organs and tissues, including the
brain. Zinc therapy is currently used to treat WD in clinical practice.
It is safer than chelating agents and has about the same efﬁcacy. It is
usually proscribed as a form of maintenance therapy, and it is taken
byWD patients for the entirety of their lives. Studies on AD patients
suggest that zinc therapy may have some efﬁcacy for AD (Brewer,
2012; Constantinidis, 1992; Hoogenraad, 2011). However, zinc
supplementation takenwithoutmedical supervision can raise some
concerns. Also, the use of oral zinc supplements has been associated
with copper deﬁciency myelopathy, which is an irreversible
neurologic syndrome (Gabreyes et al., 2013). Excess zinc intake
because of the chronic use of denture cream may result in hypo-
cupremia and serious neurologic disease (Nations et al., 2008).
Overall, there are great differences in zinc status worldwide
because of the variability in diet regimens and in zinc-related
policies (WHO, 2013). It is advisable to monitor zinc supplemen-
tation in individuals with copper metabolism abnormalities and to
alter monitoring practices as needed in accordance to zinc policies
globally.
6. Conclusions and future perspectives
The present article has reviewed current knowledge about
copper dyshomeostasis. It has also explored AD pathogenesis and
the interplay between genetics and dietary copper intake in
determining susceptibility to the AD copper phenotype. These data
strongly support the hypothesis that copper balance is a modiﬁable
factor that could reduce AD risk in certain individuals who can
implement a low-copper diet.
Although scientiﬁc evidence supporting the detrimental effects
of copper on cognition and brain health ismostly consistent, it is not
yet conclusive. It will remain inconclusive until the gene mutations
that cause copper dysfunction in AD individuals are clearly identi-
ﬁed. We believe this identiﬁcation will occur soon (Squitti et al.,
2013c). However, healthful and inexpensive dietary precautions,
monitored by medical professionals (who would introduce a low-
copper diet only to people with conﬁrmed altered copper meta-
bolism), are fully justiﬁed and may be currently implemented to
safely modify copper-related risk. Speciﬁcally, applying the WHO
recommendation for a recommended dietary allowance of 0.9 mg
per day could be sufﬁcient. Indirect and direct biochemical testing to
detect serum non-Cp copper can identify individuals with altered
copper metabolism. They can also monitor the effectiveness of a
dietary strategy desired to correct this condition. We suggest that
individuals with highecopper-related AD risk should adopt a low-
copper diet, that is, increase the quantity of low-copper foods,
whereas reducing the quantity of high-copper foods, fatty foods, and
alcohol consumption (that affects liver functionality). These in-
dividuals should also take zinc supplements, provided this can be
doneundermedical supervision. Although this advice is simple, safe,
healthy, and inexpensive,medical supervision is needed toverify the
diet’s effectiveness and avoid copper deﬁciency and its adverse
sequelae, and such supervision may not be feasible in all locales.
Future perspectives of this dietary strategy involve the improve-
ment of screening tests for individualswith high-copper risk based on
genetics andthedevelopmentofanti-coppermedical foods, including,
for example, speciﬁc zinc supplements. Additionally, an increased
understanding of genetics offers us our greatest hope of identifying
high-risk individuals. Although genetic studies have indicated that
copper-handling genes modulate copper dyshomeostasis in AD,further investigations are needed to enrich our current understanding
of the genetics of the AD copper phenotype. Greater understanding
could allow us to implement genetic tests that could be used to
identify an individual’s genetic predisposition.
Anti-copper agents are currently the ﬁrst line of therapy for
treating WD. Little information has been collected about their ef-
ﬁcacy to modify the clinical history of AD (as reviewed in Squitti
and Salustri, 2009; Squitti and Zito, 2009). Hopefully, they will
also prove effective in slowing, stopping, or reversing disease pro-
gression in AD copper phenotype patients.Disclosure statement
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